NCT03342001 is a Phase 4 clinical trial of Calcitonin in Hypothyroidism, sponsored by University of Maryland, Baltimore.

Who is sponsoring NCT03342001?

NCT03342001 is sponsored by University of Maryland, Baltimore.

What drugs are being tested in NCT03342001?

Interventions in NCT03342001: Calcitonin.

What condition does NCT03342001 study?

NCT03342001 studies Hypothyroidism.

Is NCT03342001 still recruiting?

NCT03342001 is currently completed. Last updated 21 February 2022.

Are results published for NCT03342001?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2022-02-21 · How we verify

NCT03342001

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hypothyroidism Treated With Calcitonin

Completed Phase 4 Results posted Last updated 21 February 2022

What this trial tests

Phase 4 trial testing Calcitonin in Hypothyroidism in 11 participants. Completed in 14 August 2019.

Timeline

18 June 2018

Primary endpoint
30 June 2019

14 August 2019

Quick facts

Lead sponsor	University of Maryland, Baltimore
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	11
Start date	18 June 2018
Primary completion	30 June 2019
Estimated completion	14 August 2019
Sites	1 location across United States

Drugs / interventions tested

Calcitonin (CALCITONIN) — full drug profile →

Conditions studied

Hypothyroidism — all drugs for Hypothyroidism →

Sponsor

University of Maryland, Baltimore

Who can join

Adults 18 to 88, any sex, with Hypothyroidism. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Modified City of Hope Quality of Life Questionnaire for Patients With Thyroid Disease Primary · 6 weeks

questionnaire to assess quality of life, 40 questions, 1-10 scale with 10 indicating more severe symptoms. Total 400 points, primary assessment was change in score after 6 weeks.

Group	Value	95% CI
Treatment Group, Open Label	-36.33	± 39.41

Adverse events — posted to ClinicalTrials.gov

Time frame: Only during trial 6 weeks per participant. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Treatment Group, Open Label

Serious: 0/11 (0%)

Deaths: 0/11

Other adverse events (2 terms — click to expand)

Reaction	System	Treatment Group, Open Label
nausea	Gastrointestinal disorders	—
kidney stone	Renal and urinary disorders	—

Data from ClinicalTrials.gov NCT03342001 adverse events section.

Sponsor's own description

Some people with hypothyroidism have persistent symptoms despite adequate treatment with thyroid hormones. We are testing whether giving calcitonin to such people will improve their quality of life.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Calcitonin

Trials testing the same drug.

NCT05805683 — Calcitonin Therapy on Incidence and Severity of Neuropathic Pain After Spinal Cord Injury · NA · recruiting
NCT03935984 — Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity · Phase 4 · recruiting

Other recruiting trials for Hypothyroidism

Currently open trials in the same condition.

NCT07060118 — Gluten Free Diet in Hashimoto's Hypothyroidism · NA · recruiting
NCT06757712 — Periodization Resistance Training on Quality of Life in Females With Hypothyroidism · NA · recruiting
NCT06731764 — Novel Approaches to the Treatment of Hypothyroidism · Phase 2, PHASE3 · recruiting
NCT06826248 — Clinical Efficacy of Darqeen Capsule for the Management of Hypothyroidism Associated with Female Reproductive Hormonal I · EARLY_PHASE1 · active not recruiting
NCT07421869 — SNUH Immune Checkpoint Inhibitor-induced Hypothyroidism Recovery Trial · NA · recruiting

Other University of Maryland, Baltimore trials

Trials by the same sponsor.

NCT07537413 — Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia · Phase 4 · not yet recruiting
NCT07221799 — OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis · Phase 1 · not yet recruiting
NCT07094672 — Development of an Opioid Withdrawal Clinical Outcome Assessment · not yet recruiting
NCT06583239 — Hub-Based Engagement Navigator Service to Reduce CSC Disengagement · NA · not yet recruiting
NCT07536412 — Decision Aid Efficacy in Low Risk Thyroid Cancer · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03342001 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Maryland, Baltimore
Last refreshed: 21 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03342001.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing